Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 5Terminated 2Recruiting 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Adrenocortical Carcinoma 1

Interventions

lutetium Lu 177 dotatate 6Everolimus 6lanreotide 5anlotinib 5Temozolomide 5Injections 4Dexmedetomidine 4Cisplatin 4surufatinib 3Thyrotropin Alfa 3Sodium Chloride 3Saline Solution 3Fluorodeoxyglucose F18 3Blood Specimen Collection 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3(177)Lu-DOTA-EB-TATE 3sintilimab 2penpulimab 2cabozantinib 2Surgical Procedures, Operative 2Sorafenib 2Rosiglitazone 2Radiotherapy 2Radiofrequency Ablation 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Metformin 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Mitotane × Endocrine × Clear all
NCT00777244 2017-05-08

ADIUVO

University of Turin, Italy

Phase 3 Unknown
200 enrolled
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡